Apogee Therapeutics: Company & Acquisition Overview

Company Profile

Core Focus and Pipeline

Apogee Therapeutics is a clinical-stage biotechnology firm focused on developing differentiated biologics for inflammatory and immunology conditions. Its primary therapeutic areas include atopic dermatitis, COPD, asthma, and related inflammatory diseases. The company’s flagship candidate, APG777 (also known as zumilokibart), is a long-acting IL-13 inhibitor that recently delivered positive Phase 2 results and is advancing to Phase 3 trials for atopic dermatitis. Source 1

Leadership & Operations

The company is led by an experienced management team and is headquartered in the Boston area, where it continues to advance next-generation immunology therapies. Details about its leadership are available on the corporate “About Us” page. Source 2

AbbVie Acquisition Announcement

Deal Terms

In a landmark transaction announced on Monday, June 22, 2026, AbbVie agreed to acquire Apogee Therapeutics in an all-cash deal valued at approximately $10.9 billion. The acquisition marks AbbVie’s largest buyout in more than five years. Source 4

Strategic Rationale

The deal is expected to strengthen AbbVie’s immunology and inflammation portfolio ahead of the upcoming loss of exclusivity for Skyrizi. It adds late-stage assets, including APG777/zumilokibart, that target atopic dermatitis, asthma, and eosinophilic esophagitis. Source 8

Market Reaction & Timeline

Apogee’s shares rose roughly 20% following the positive Phase 2 data that preceded the acquisition announcement. While an exact closing date has not been disclosed, such transactions typically close within six to twelve months, subject to regulatory approvals. Source 9

FAQ

What diseases is Apogee Therapeutics targeting? Apogee focuses on inflammatory and immunology conditions, primarily atopic dermatitis (eczema), COPD, asthma, and eosinophilic esophagitis.

What is APG777 / zumilokibart? APG777 (also referred to as zumilokibart) is Apogee’s lead long-acting IL-13 inhibitor currently advancing into Phase 3 trials for atopic dermatitis.

How much is AbbVie paying to acquire Apogee? AbbVie is acquiring Apogee in an all-cash deal valued at roughly $10.9 billion.

Why is AbbVie buying Apogee Therapeutics? The acquisition strengthens AbbVie’s immunology pipeline and helps offset upcoming patent expirations for its flagship drug Skyrizi.

When was the acquisition announced? The deal was publicly announced on Monday, June 22, 2026.

What is the expected closing timeline for the transaction? While an exact closing date has not been disclosed, such deals typically close within six to twelve months, pending regulatory approvals.